A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

Inclusion Criteria Concurrent Medication: Allowed: * Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria. * Acyclovir as acute treatment for herpes outbreaks. Concurrent Treatment: Allowed: * Limited electron-beam radiation therapy to non-marker lesions for treatment of Kaposi's sarcoma. Patients must have: * Documented HIV infection. * Kaposi's sarcoma. * No current constitutional signs of HIV disease or AIDS-defining conditions other than Kaposi's sarcoma. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active malignancy other than Kaposi's sarcoma, cutaneous basal cell carcinoma, or in situ carcinoma of the cervix. * Current significant cardiac disease or anomaly (including prolonged QTC on EKG). * Abnormal cardio-thoracic ratio on chest x-ray. Concurrent Medication: Excluded: * Antiretroviral agents, including ddI, ddC, AZT, and d4T. * Immunosuppressive agents. * Investigational HIV drugs/therapies including vaccines (except those on treatment IND for approved indications). * Other anti-Kaposi's sarcoma/HIV drugs. * Corticosteroids (other than topical). * Biologic response modifiers. * Megestrol acetate. * Agents known to cause neutropenia. * Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly. * Cytotoxic chemotherapy. Concurrent Treatment: Excluded: * Radiation therapy including electron beam irradiation (other than limited electron-beam radiation to non-marker lesions for treatment of Kaposi's sarcoma). Patients with the following prior conditions are excluded: * Prior history of significant cardiac disease or anomaly. * History of agranulocytosis or severe grade 3 drug-induced neutropenia or documented abnormalities in granulocyte function. Prior Medication: Excluded: * AZT within 14 days prior to study entry. * Acyclovir as prophylaxis for herpes within 48 hours prior to study entry. Excluded within 30 days prior to study entry: * Interferon. * Biologic response modifiers. * Cytotoxic chemotherapy. Prior Treatment: Excluded within 30 days prior to study entry: * Blood or cellular blood product. Active illicit drug abuse (specifically cocaine, amyl nitrate, heroin, or other cardioactive agents).